|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel R, Miller K and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Funt SA and Rosenberg JE: Systemic,
perioperative management of muscle-invasive bladder cancer and
future horizons. Nat Rev Clin Oncol. 14:221–234. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Santoni M, Catanzariti F, Minardi D,
Burattini L, Nabissi M, Muzzonigro G, Cascinu S and Santoni G:
Pathogenic and diagnostic potential of BLCA-1 and BLCA-4 nuclear
proteins in urothelial cell carcinoma of human bladder. Adv Urol.
2012:3974122012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Salomaa V, Havulinna A, Saarela O, Zeller
T, Jousilahti P, Jula A, Muenzel T, Aromaa A, Evans A, Kuulasmaa K
and Blankenberg S: Thirty-one novel biomarkers as predictors for
clinically incident diabetes. PLoS One. 5:e101002010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Izadi F, Zarrini HN, Kiani G and Jelodar
NB: A comparative analytical assay of gene regulatory networks
inferred using microarray and RNA-seq datasets. Bioinformation.
12:340–346. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Deandrés-Galiana EJ, Fernández-Martínez
JL, Saligan LN and Sonis ST: Impact of microarray preprocessing
techniques in unraveling biological pathways. J Comput Biol.
23:957–968. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Colantuoni C, Henry G, Zeger S and Pevsner
J: SNOMAD (Standardization and NOrmalization of MicroArray Data):
web-accessible gene expression data analysis. Bioinformatics.
18:1540–1541. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gautier L, Cope L, Bolstad BM and Irizarry
RA: Affy-analysis of Affymetrix GeneChip data at the probe level.
Bioinformatics. 20:307–315. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Dazard JE, Choe M, LeBlanc M and Rao JS: R
package PRIMsrc: Bump hunting by patient rule induction method for
survival, regression and classification. Proc Am Stat Assoc.
2015:650–664. 2015.PubMed/NCBI
|
|
11
|
Robin X, Turck N, Hainard A, Tiberti N,
Lisacek F, Sanchez JC and Müller M: pROC: An open-source package
for R and S+ to analyze and compare ROC curves. BMC bioinformatics.
12:772011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Subramanian A, Tamayo P, Mootha VK,
Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub
TR, Lander ES and Mesirov JP: Gene set enrichment analysis: A
knowledge-based approach for interpreting genome-wide expression
profiles. Proc Natl Acad Sci USA. 102:15545–15550. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhao M, He XL and Teng XD: Understanding
the molecular pathogenesis and prognostics of bladder cancer: An
overview. Chin J Cancer Res. 28:92–98. 2016.PubMed/NCBI
|
|
14
|
Dadhania V, Czerniak B and Guo CC:
Adenocarcinoma of the urinary bladder. Am J Clin Exp Urol. 3:51–63.
2015.PubMed/NCBI
|
|
15
|
Boustead GB, Fowler S, Swamy R,
Kocklebergh R and Hounsome L: Stage, grade and pathological
characteristics of bladder cancer in the UK: British association of
urological surgeons (BAUS) urological tumour registry. BJU Int.
113:924–930. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hong Z, Li H, Li L, Wang W and Xu T:
Different expression patterns of histone H3K27 demethylases in
renal cell carcinoma and bladder cancer. Cancer Biomark.
18:125–131. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Nandagopal L and Sonpavde G: Circulating
biomarkers in bladder cancer. Bladder Cancer. 2:369–379. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yang J, Platt LT, Maity B, Ahlers KE, Luo
Z, Lin Z, Chakravarti B, Ibeawuchi SR, Askeland RW, Bondaruk J, et
al: RGS6 is an essential tumor suppressor that prevents bladder
carcinogenesis by promoting p53 activation and DNMT1
downregulation. Oncotarget. 7:69159–69172. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wang J, Zhang X, Wang L, Dong Z, Du L,
Yang Y, Guo Y and Wang C: Downregulation of urinary cell-free
microRNA-214 as a diagnostic and prognostic biomarker in bladder
cancer. J Surg Oncol. 111:992–999. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Gogalic S, Sauer U, Doppler S, Heinzel A,
Perco P, Lukas A, Simpson G, Pandha H, Horvath A and Preininger C:
Validation of a protein panel for the non-invasive detection of
recurrent non-muscle invasive bladder cancer. Biomarkers.
22:674–681. 2017.PubMed/NCBI
|
|
21
|
Urquidi V, Netherton M, Gomes-Giacoia E,
Serie DJ, Eckel-Passow J, Rosser CJ and Goodison S: A microRNA
biomarker panel for the non-invasive detection of bladder cancer.
Oncotarget. 7:86290–86299. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Li Y, Huang J, Sun J, Xiang S, Yang D,
Ying X, Lu M, Li H and Ren G: The transcription levels and
prognostic values of seven proteasome alpha subunits in human
cancers. Oncotarget. 8:4501–4519. 2017.PubMed/NCBI
|
|
23
|
Kavalieris L, O'Sullivan P, Frampton C,
Guilford P, Darling D, Jacobson E, Suttie J, Raman JD, Shariat SF
and Lotan Y: Performance characteristics of a multigene urine
biomarker test for monitoring for recurrent urothelial carcinoma in
a multicenter study. J Urol. 197:1419–1426. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lin ML, Park JH, Nishidate T, Nakamura Y
and Katagiri T: Involvement of maternal embryonic leucine zipper
kinase (MELK) in mammary carcinogenesis through interaction with
Bcl-G, a pro-apoptotic member of the Bcl-2 family. Breast Cancer
Res. 9:R172007. View
Article : Google Scholar : PubMed/NCBI
|
|
25
|
Spitz MR, Gorlov IP, Dong Q, Wu X, Chen W,
Chang DW, Etzel CJ, Caporaso NE, Zhao Y, Christiani DC, et al:
Multistage analysis of variants in the inflammation pathway and
lung cancer risk in smokers. Cancer Epidemiol Biomarkers Prev.
21:1213–1221. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Davis TA, Loos B and Engelbrecht AM:
AHNAK: The giant jack of all trades. Cell Signal. 26:2683–2693.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Sheppard HM, Feisst V, Chen J, Print C and
Dunbar PR: AHNAK is downregulated in melanoma, predicts poor
outcome, and may be required for the expression of functional
cadherin-1. Melanoma Res. 26:108–116. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Sudo H, Tsuji AB, Sugyo A, Abe M, Hino O
and Saga T: AHNAK is highly expressed and plays a key role in cell
migration and invasion in mesothelioma. Int J Oncol. 44:530–538.
2014. View Article : Google Scholar : PubMed/NCBI
|
